8-K: Kymera's KT-621 Shows Dupilumab-Like Efficacy in AD Trial

Kymera Therapeutics announced positive Phase 1b results for its oral STAT6 degrader KT-621 in atopic dermatitis, demonstrating deep STAT6 degradation and robust clinical improvements comparable to Dupilumab.

Summary

• KT-621, a first-in-class, oral STAT6 degrader, achieved deep STAT6 degradation (median 98% in blood, 94% in skin) across 100 mg and 200 mg once-daily doses over 28 days in the BroADen Phase 1b atopic dermatitis patient trial.
• Demonstrated robust reductions in Type 2 biomarkers, including a median TARC reduction of 74% (in patients with similar baseline TARC to Dupilumab AD studies), up to 73% Eotaxin-3 reduction, up to 14% IgE reduction, and up to 56% IL-31 reduction.
• Significantly downregulated core Type 2 inflammation and AD disease-relevant gene sets in skin lesions, comparable to published data for Dupilumab at Week 4.
• Achieved a 63% overall mean reduction in EASI (Eczema Area and Severity Index) score, with EASI-50 responder rate of 76%, EASI-75 of 29%, and vIGA-AD 0/1 responder rate of 22%.
• Showed robust and consistent reductions in itch (40% mean reduction in Peak Pruritus NRS, 44% mean reduction in SCORAD-Itch) and improved sleep (76% overall mean reduction in SCORAD-Sleeplessness).
• Demonstrated improvements in patient quality of life (POEM and DLQI scores exceeding the minimum clinically important difference, MCID).
• Provided early evidence of activity in comorbid asthma (up to 33% FeNO reduction, 56% median FeNO reduction in asthma patients, 100% ACQ-5 responder rate) and allergic rhinitis (57% TNSS responder rate, 33% RQLQ responder rate).
• KT-621 was well-tolerated with a favorable safety profile, similar to the Phase 1a healthy volunteer trial, with no SAEs, severe AEs, dose-dependent TEAEs, related TEAEs, or discontinuations. No AEs of conjunctivitis, herpes infections, or arthralgias were observed.

Sentiment

Score: 9

Explanation: The Phase 1b results for KT-621 are highly positive, demonstrating strong efficacy and a favorable safety profile comparable to or exceeding Dupilumab, a leading injectable biologic, but with the significant advantage of being an oral medication. This positions KT-621 as a potentially disruptive therapy in a large, underserved market.

Positives

• Achieved deep and sustained STAT6 degradation in both blood (median 98%) and skin (median 94%) with strong translation from healthy volunteer studies.
• Demonstrated robust reductions in key disease-relevant Type 2 inflammation biomarkers including TARC, Eotaxin-3, IL-31, and FeNO.
• Showed significant clinical improvements in AD severity, with a 63% overall mean EASI reduction, 76% EASI-50 responder rate, and 29% EASI-75 responder rate.
• Achieved meaningful reductions in itch (40% mean PPNRS reduction, 44% mean SCORAD-Itch reduction) and improved sleep (76% mean SCORAD-Sleeplessness reduction).
• Positive impact on patient quality of life, with POEM and DLQI improvements exceeding the minimum clinically important difference (MCID).
• Favorable safety and tolerability profile, similar to placebo, with no serious adverse events, dose-dependent adverse events, or discontinuations.
• Early evidence of efficacy in comorbid asthma and allergic rhinitis suggests broader potential for KT-621 across Type 2 inflammatory diseases.
• Results are consistently in line with or numerically exceeded published data for Dupilumab at Week 4 across multiple key efficacy endpoints and biomarkers, offering a potential 'Dupilumab-in-a-pill' profile.

Negatives

• IgE reduction was modest (up to 14%), though more robust IgE reduction often necessitates several months of pathway suppression.
• Cross-study comparisons to Dupilumab are not head-to-head and may not be directly comparable due to differences in molecule composition, trial protocols, dosing regimens, and patient populations and characteristics.

Risks

• The timing and anticipated results of current and future preclinical studies and clinical trials may vary.
• There is a risk of delay in any current and future preclinical studies or clinical trials or the development of drug candidates.
• Results of prior preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical studies and clinical trials, including those for KT-621.
• Cross-trial comparisons may not be reliable as no head-to-head trials have been completed for KT-621 to Dupilumab, and Phase 1 clinical data for KT-621 may not be directly comparable to Dupilumab's clinical data due to differences in molecule composition, trial protocols, dosing regimens, and patient populations and characteristics.
• The ability to successfully demonstrate the safety and efficacy of drug candidates is not guaranteed.
• The timing and outcome of any interactions with regulatory authorities are uncertain.
• Obtaining, maintaining, and protecting intellectual property is subject to risks.
• Relationships with existing and future collaboration partners may face challenges.
• Impacts of current macroeconomic and geopolitical events could adversely affect operations.

Future Outlook

Kymera plans to initiate the BREADTH Phase 2b study in asthma in the first quarter of 2026 and expects Phase 2b data readout for KT-621 in moderate to severe AD patients by mid-2027. The company anticipates its cash runway will extend into the second half of 2028.

Management Comments

• "KT-621 clinical data continues to support STAT6 degradation as a potentially transformative approach for Type 2-driven inflammatory diseases, with a once-a-day, oral drug." Nello Mainolfi, PhD, Founder, President and Chief Executive Officer.
• "Results further validate KT-621s oral, biologics-like profile with potential to broaden clinical access for patients and disrupt a biologics-dominated Type 2 market in AD, asthma, and beyond." Nello Mainolfi, PhD, Founder, President and Chief Executive Officer.
• "There remains a clear need for new oral therapies that can address the underlying biology of the disease while potentially offering patients greater convenience." Eric Simpson, MD, MCR, Frances J. Storrs Medical Dermatology Professor and Director of CLEAR Eczema Center, Oregon Health & Science University (quoted in presentation).

Industry Context

The immunology market is large and underserved, with millions of patients lacking access to advanced systemic therapies, which are predominantly injectable biologics. Oral small molecule degraders like KT-621 have the potential to revolutionize treatment by offering biologics-like activity with the convenience of a pill, addressing limitations of injectables such as inconvenience, immunogenicity risks, and high manufacturing costs. STAT6 is a highly validated but undrugged target in the IL-4/IL-13 pathway, clinically validated by Dupilumab across multiple Type 2 allergic and atopic diseases.

Comparison to Industry Standards

• KT-621's effects on Type 2 biomarkers and clinical endpoints were in line with or numerically exceeded published data for Dupilumab at Week 4.
• Achieved a 74% median TARC reduction, similar to Dupilumab at Week 4 when stratifying for patients with similar baseline TARC levels (e.g., Dupilumab SOLO 1/2 studies showed 74% reduction at 4 weeks with 1,937 pg/mL baseline TARC).
• Eotaxin-3 reduction (up to 73%) exceeds Dupilumab's 52-week results (51% in CRSwNP trial and 38% in asthma trial).
• IgE reduction (up to 14%) is comparable to Dupilumab data in AD studies at Week 4.
• Changes in transcriptome (core Type 2 inflammation gene set) in skin lesions were comparable to published data for Dupilumab at Week 4.
• Mean % Change in EASI (-63%) compares favorably to Dupilumab 300 mg Q2W (-52% at D28 Ph3).
• EASI-50 (76%) compares favorably to Dupilumab (57% at D28 Ph3).
• EASI-75 (29%) is comparable to Dupilumab (28% at D28 Ph3).
• Mean % Change in PPNRS (-40%) compares favorably to Dupilumab (-33% at D28 Ph3).
• vIGA-AD 0 and 1 (22%) compares favorably to Dupilumab (12% at D28 Ph3).
• Mean % Change in % Body Surface Area (-55%) compares favorably to Dupilumab (-36% at D28 Ph3).
• POEM Responders (73%) are comparable to Dupilumab (69% at Week 16).
• DLQI Responders (61%) are comparable to Dupilumab (69% at Week 16).
• Median FeNO reduction (56% in comorbid asthma patients) exceeds Dupilumab (31%) in asthma studies at Week 4.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, validating the company's targeted protein degradation platform and increasing the potential value of KT-621. Reduced clinical risk for a key pipeline asset.
• Patients (AD, asthma, allergic rhinitis): Potential for a convenient, oral, biologics-like therapy that could significantly improve quality of life, reduce disease burden, and expand access to advanced treatments.
• Healthcare Providers: Offers a new, potentially highly effective oral treatment option for Type 2 inflammatory diseases, simplifying administration compared to injectables.
• Competitors: Increased competitive pressure, particularly for injectable biologics like Dupilumab, if KT-621 continues to demonstrate comparable efficacy with an oral advantage.

Next Steps

• Continue the BroADen2 Phase 2b study in AD.
• Start the BREADTH Phase 2b study in asthma in Q1 2026.
• Anticipate Phase 2b data readout for KT-621 in moderate to severe AD by mid-2027.
• Support subsequent Phase 3 trials across multiple dermatology, GI, and respiratory indications.

Key Dates

Recommendation

The Phase 1b results for KT-621 are exceptionally strong, demonstrating efficacy and safety comparable to or even numerically superior to Dupilumab, a blockbuster biologic, but with the significant advantage of being an oral therapy. This positions KT-621 as a potential game-changer in the large and underserved Type 2 inflammatory disease market. The data de-risks the asset significantly and suggests a high probability of success in later-stage trials. The oral formulation addresses a major unmet need for patient convenience and could capture substantial market share. The company's cash runway into H2 2028 provides financial stability for continued development. This represents a compelling investment opportunity.

Keywords

Kymera Therapeutics, KT-621, STAT6 degrader, atopic dermatitis, AD, immunology, oral medicine, targeted protein degradation, TPD, Phase 1b, clinical trial, Dupilumab, EASI, TARC, Eotaxin-3, IL-31, FeNO, asthma, allergic rhinitis